Yapeng Su

K99-Damon Runyon Fellow @FredHutch, trainee of @labheath, David Baltimore, and Leroy Hood @Caltech & @isbsci. Systems Biology, Immunology, Cancer, Engineering

[Yapeng Su @SuYapeng]

@delafuentelab @acad_euro Congrats Cesar and academia europea! Very well deserved!

[Yapeng Su @SuYapeng]

@JerzySzablowski Congratulations Jerzy and Rice! Very well deserved!

[Yapeng Su @SuYapeng]

@OncoAdvLukas @RongFan8 @MinaXu7 @yalepathology @zhou_jingtian @arcinstitute @theNCI Agreed! These transformative technologies are revealing so much biology of cancer and our immune system!

[Yapeng Su @SuYapeng]

@RongFan8 @MinaXu7 @yalepathology @zhou_jingtian @arcinstitute @theNCI Congrats Rong, Mina and Jingtian! This is truly beautiful work 🤩

[Yapeng Su @SuYapeng]

@StimulatedRaman @deniswirtz @UCSD @UCSDHealth @ucsdbiosciences @UCSDnews @SallyRideSci @UCSDGiving @ucsdbe @UCSDJacobs @Yajuan_02 Congratulations Lingyan and Yajuan!

[Yapeng Su @SuYapeng]

@clairebedbrook Congrats Claire and team! Beautiful story!🤩

[Yapeng Su @SuYapeng]

@sriv4000 @SciImmunology Congrats Shivani and team! Beautiful work!🤩

[Yapeng Su @SuYapeng]

@JerzySzablowski Congrats Jerzy! Truly well deserved!🤩

[Yapeng Su @SuYapeng]

@RuellaLab @EvanWeberPhD @Shan_Liu_ @PuneethGuru_ @MarcoRuella @MaayanLevyPhD @PennMedicine @PennMedCSO @PennCancer @CellCellPress Congrats Marco, Maayan, Shan, Puneeth and the entire team on this beautiful work! 🤩

[Fred Hutch Cancer Center @fredhutch]

Fred Hutch is bringing the 🔥 to #STATMadness!

@SuYapeng and team uncovered how the sugar mannose supercharges T cells and boosts tumor control.

Let’s run up the score — vote in @statnews’ bracket-style tournament now! 👉 https://t.co/75wMFL776P

[Yapeng Su @SuYapeng]

@JerzySzablowski @SloanFoundation Congrats Jerzy and Sloan!

[Yapeng Su @SuYapeng]

@harriswangnyc @Columbia @ColumbiaMed @ColumbiaSysBio Congrats Harris and Columbia! 🤩

[Science in Seattle @science_seattle]

Two obstacles in #CancerImmunotherapy are tumor-infiltrating T cell exhaustion and mitochondrial dysfunction.

Drs. @SuYapeng & Philip Greenberg at @FredHutch & @UW identified the E3 ubiquitin ligase KLHL6 as a dual-negative regulator of both.

🔎 Abstract: https://t.co/DMc53M3U3W

[Yapeng Su @SuYapeng]

@RongFan8 @YaleEngineering @YaleMed @Yale @Penn Congrats Rong, Yale and the entire team! Beautiful work ！🤩🎊🥳

[Zihai Li, MD, PhD @Zihai]

This @Nature study (https://t.co/GIGAZHozCz) shows that loss of the ubiquitin ligase KLHL6 in Tex cells prevents TOX degradation, stabilizing exhaustion and mitochondrial dysfunction. Another case linking proteostasis to T cell exhaustion. Congrats to @HutchGreenberg, Guideng Li.

[nature @Nature]

Nature research paper: The ubiquitin ligase KLHL6 drives resistance to CD8+ T cell dysfunction

https://t.co/o0zHSvtR3T

[Yapeng Su @SuYapeng]

"Huge thanks to an amazing team, mentors, and collaborators at @fredhutch @FH_IRC and globally
📄 Nature: “The ubiquitin ligase KLHL6 drives resistance to CD8⁺ T cell dysfunction”
🔗 (https://t.co/BUevIoU2HO)

[Yapeng Su @SuYapeng]

🚨 Excited to share our collaborative work in @Nature ! 🚨
We identify KLHL6, an E3 ubiquitin ligase, as a key regulator that protects CD8⁺ T cells from both exhaustion and mitochondrial dysfunction — two major barriers in cancer immunotherapy. https://t.co/BUevIoTuSg🧵👇

[Yapeng Su @SuYapeng]

📌 Take-home message:
Targeting ubiquitin-mediated proteostasis can coordinate cell state and metabolism in T cells.
KLHL6 is a multifunctional, clinically actionable target for next-gen immunotherapy.